Revised forecast
Fiscal year ending December 2026 · Six months and full yearPrevious forecast published 5 March 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Amid a gradual recovery in global demand, sales in the Dental, DCI, Surgical and Machine Tool businesses remained solid. Improved utilization of the head office plant and the yen's depreciation also contributed, and results for the consolidated cumulative second-quarter period exceeded the forecast. The full-year forecast was reviewed based on results for the consolidated cumulative second-quarter period, recent business trends and assumed exchange rates. The assumed exchange rates from the third quarter onward are ¥155.00 per US dollar and ¥180.00 per euro.
| Item | Details |
|---|---|
| Net Sales | 2Q cumulative 44,374 / Full year 90,185 → Cumulative second quarter (current-period actual results) 47,234 / Full year 94,480（2Q cumulative 6.4 / Full year 4.8） |
| Operating profit | 2Q cumulative 7,481 / Full year 16,215 → Cumulative second quarter (current-period actual results) 10,012 / Full year 18,649（2Q cumulative 33.8 / Full year 15） |
| Ordinary income | 2Q cumulative 7,501 / Full year 16,091 → Cumulative second quarter (current-period actual results) 11,577 / Full year 19,062（2Q cumulative 54.3 / Full year 18.5） |
| Profit attributable to owners of the parent | 2Q cumulative 5,308 / Full year 11,193 → Cumulative second quarter (current-period actual results) 8,144 / Full year 13,544（2Q cumulative 53.4 / Full year 21） |
| Net income per share | 2Q cumulative 63.53 / Full year 133.96 → Cumulative second quarter (current-period actual results) 98.07 / Full year 163.1 |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Six months and full year |
| Publication date of previous forecast | 5 March 2026 |
| Previous-period results | 2Q cumulative Net Sales 39,189 / EBITDA 10,390 / Operating profit 7,587 / Ordinary income 6,930 / Interim net income attributable to owners of the parent 3,510 / Interim net income per share 41.84 / Full year Net Sales 81,179 / EBITDA 19,899 / Operating profit 14,089 / Ordinary income 16,933 / Profit attributable to owners of the parent -2,398 / Net income per share -28.7 |
| Reason for the revision | Amid a gradual recovery in global demand, sales in the Dental, DCI, Surgical and Machine Tool businesses remained solid. Improved utilization of the head office plant and the yen's depreciation also contributed, and results for the consolidated cumulative second-quarter period exceeded the forecast. The full-year forecast was reviewed based on results for the consolidated cumulative second-quarter period, recent business trends and assumed exchange rates. The assumed exchange rates from the third quarter onward are ¥155.00 per US dollar and ¥180.00 per euro. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was attributable to solid sales in the Dental, DCI, Surgical and Machine Tool businesses against a backdrop of a gradual recovery in global demand, improved utilization of the head office plant and the yen's depreciation. The full-year forecast was reviewed based on results for the cumulative second-quarter period, recent business trends and assumed exchange rates.